Kanada - engelska - Health Canada

valeant canada lp / valeant canada s.e.c. - conjugated estrogens - tablet - 0.3mg - conjugated estrogens 0.3mg - estrogens

Kanada - engelska - Health Canada

valeant canada lp / valeant canada s.e.c. - conjugated estrogens - tablet - 0.9mg - conjugated estrogens 0.9mg - estrogens

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate; conjugated oestrogens - oral tablet - 10mg ; 625microgram

USA - engelska - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

USA - engelska - NLM (National Library of Medicine)

method pharmaceuticals, llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 0.625 mg - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: 1.       known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2.       known or suspected estrogen-dependent ne

Irland - engelska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 0.625 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Irland - engelska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625 mg/2.5 milligram(s) - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Irland - engelska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 1.25 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Irland - engelska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625mg/5m percent volume/volume - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Irland - engelska - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain